Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $34.42.

Several brokerages have commented on SNDX. HC Wainwright restated a “buy” rating and set a $41.00 price target on shares of Syndax Pharmaceuticals in a research note on Thursday, June 6th. Scotiabank lowered Syndax Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday. Stifel Nicolaus upped their price target on Syndax Pharmaceuticals from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. JPMorgan Chase & Co. restated an “overweight” rating and set a $34.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, May 21st. Finally, Citigroup lowered their target price on Syndax Pharmaceuticals from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, May 9th.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of SNDX. CWM LLC lifted its holdings in Syndax Pharmaceuticals by 415.3% during the 4th quarter. CWM LLC now owns 1,685 shares of the company’s stock worth $36,000 after buying an additional 1,358 shares during the last quarter. MeadowBrook Investment Advisors LLC bought a new position in Syndax Pharmaceuticals during the 4th quarter worth approximately $37,000. Quadrant Capital Group LLC lifted its holdings in Syndax Pharmaceuticals by 158.3% during the 4th quarter. Quadrant Capital Group LLC now owns 2,441 shares of the company’s stock worth $53,000 after buying an additional 1,496 shares during the last quarter. Annandale Capital LLC bought a new position in Syndax Pharmaceuticals during the 3rd quarter worth approximately $67,000. Finally, Signaturefd LLC lifted its holdings in Syndax Pharmaceuticals by 2,874.6% during the 4th quarter. Signaturefd LLC now owns 3,748 shares of the company’s stock worth $81,000 after buying an additional 3,622 shares during the last quarter.

Syndax Pharmaceuticals Trading Down 2.9 %

Syndax Pharmaceuticals stock opened at $20.11 on Tuesday. The firm has a market capitalization of $1.71 billion, a P/E ratio of -6.25 and a beta of 1.01. The stock has a fifty day moving average price of $20.88 and a 200 day moving average price of $21.31. Syndax Pharmaceuticals has a 52 week low of $11.22 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.11. During the same period last year, the business earned ($0.59) earnings per share. As a group, equities analysts predict that Syndax Pharmaceuticals will post -3.57 EPS for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).